Delivery Order SPE2DB22D3004-SPE2DB25FRU03
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $35,913.34 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with the contractor's corporate headquarters location. The award represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count quantity, with a ceiling value of $4,245.12. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation and is scheduled for ultimate completion by July 28, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 1, 2025, by the Defense Logistics Agency's Medical Supply Chain to provide Ondansetron ODT 4 mg tablets (30-count) with a firm fixed price ceiling value of $5,173.92. The order is scheduled for completion by August 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs, consistent with...
- The Defense Logistics Agency awarded a delivery order valued at $4,958.04 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count) with a ceiling value of $1,254.19 on August 4, 2025. This firm fixed-price delivery order, which is scheduled for completion by August 5, 2025, represents a non-competitive set-aside award under AmerisourceBergen's existing contract vehicle with DLA. The pharmaceutical distributor will perform the work at its corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $7,389.26. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $13.45K to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999.99M ceiling value and extends...
- The Defense Logistics Agency awarded a delivery order valued at $2,646.18 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 5, 2025. This contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRU03Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,413.45 for Ondansetron ODT 4 mg tablets (30-count supply) on August 1, 2025, with a completion date of August 4, 2025. This non-competitive, firm fixed price delivery order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of the company's extensive pharmaceutical supply relationship with DLA, supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026 that enables comprehensive global pharmaceutical support for military healthcare programs. AmerisourceBergen, as a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for the Defense Health Agency and other federal healthcare systems, supplying an extensive portfolio of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains through competitively awarded delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/1/25 |